GONE webinar – Moxidectin Q&A session – Summary report

Overview

Moxidectin has advanced through several stages of development, from preclinical trials to approval by the United States Food and Drug Administration in 2018. The Phase 2 and 3 studies demonstrated that moxidectin offers longer-lasting suppression of microfilarial density compared with ivermectin, an important element for maintaining transmission control. Moxidectin has a similar safety profile to ivermectin, with no serious adverse events assessed as related to treatment reported in completed or ongoing studies to date.